表紙
市場調査レポート

浮腫 :パイプライン分析

Edema - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229783
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
浮腫 :パイプライン分析 Edema - Pipeline Review, H2 2015
出版日: 2015年09月09日 ページ情報: 英文 44 Pages
概要

浮腫とは、身体組織内の水分によってむくむことを指し、主に足、足首、脚部に現れ、体全体に影響があります。症候は、手足がむくんで痛みや赤み、熱を伴ったり、顔面が膨張したり、腹部が膨満したり、呼吸が浅くなったり呼吸がひどくしにくくなったり、喀血したり、突然精神状態が変化したり、昏睡状態に陥ったり、筋肉痛が出たりします。浮腫は長時間座っていたり立っていたり、ある種の薬剤の使用、生理中や妊娠中のホルモンの変化、血管の感染症や傷、血栓、拡張蛇行静脈、リンパ浮腫、食物に対するアレルギーまたは虫刺され、腎臓、心臓、肝臓、甲状腺疾患、高/低血圧、塩気のある食品、脳腫瘍、頭の怪我、過酷な身体活動時に高地まなたは高熱にさらされることなどによって発生します。薬物治療は、例えばループ利尿薬またはカリウム節約利尿剤などの利尿剤を使用します。

当レポートでは、浮腫の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

浮腫概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Mirrx Therapeutics A/S
  • Otsuka Holdings Co., Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BC-1215
  • CD5-2
  • Synthetic Peptides for Edema
  • tolvaptan
  • X-0002

最近のパイプライン動向

休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7148IDB

Summary

Global Markets Direct's, 'Edema - Pipeline Review, H2 2015', provides an overview of the Edema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Edema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Edema
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Edema and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Edema pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Edema
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Edema Overview
  • Therapeutics Development
    • Pipeline Products for Edema - Overview
    • Pipeline Products for Edema - Comparative Analysis
  • Edema - Therapeutics under Development by Companies
  • Edema - Therapeutics under Investigation by Universities/Institutes
  • Edema - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Edema - Products under Development by Companies
  • Edema - Products under Investigation by Universities/Institutes
  • Edema - Companies Involved in Therapeutics Development
    • Apeptico Forschung und Entwicklung GmbH
    • Mirrx Therapeutics A/S
    • Otsuka Holdings Co., Ltd.
  • Edema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-1215 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CD-52 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Edema - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolvaptan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Edema - Recent Pipeline Updates
  • Edema - Dormant Projects
  • Edema - Product Development Milestones
    • Featured News & Press Releases
      • Jan 18, 2013: Apeptico's AP301 Receives US And EU Orphan Drug Designation For Treatment Of High Altitude Pulmonary Oedema
      • Jun 29, 2012: Apeptico Initiates Phase II Trial With AP301 In Patients With Pulmonary Oedema
      • Apr 11, 2011: APEPTICO Initiates Phase I Trial With AP301 In Pulmonary Oedema
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Edema, H2 2015
  • Number of Products under Development for Edema - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Edema - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2015
  • Edema - Pipeline by Mirrx Therapeutics A/S, H2 2015
  • Edema - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Edema Therapeutics - Recent Pipeline Updates, H2 2015
  • Edema - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Edema, H2 2015
  • Number of Products under Development for Edema - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top